Your session is about to expire
← Back to Search
Ociperlimab for Small Cell Lung Cancer
Study Summary
This trial is testing a new combination of immunotherapy drugs to treat LS-SCLC patients. The drugs are ociperlimab, tislelizumab, and cCRT. This is a phase 2 trial, which means that it is testing whether the combination of these drugs is effective and has a tolerable safety profile.
- Small Cell Lung Cancer, Limited Stage
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this research endeavor represent a pioneering effort?
"Since its initial trial in 2017, sponsored by BeiGene, Ociperlimab has been under intense scrutiny. The first phase 3 study involved 805 patients and resulted in the drug's approval. Today, there are 105 active trials for this medication taking place on 426 cities across 45 nations."
What additional research projects have been conducted with regards to Ociperlimab?
"Ociperlimab was initially tested in 2017 at Uniwersyteckie Centrum Kliniczne. Up until now, 11 completed studies have been conducted and 105 active trials are underway with a great deal of them taking place around Wichita, Kansas."
Are there any US sites currently conducting this investigation?
"This medical trial is accepting participants at 14 different sites, two of which being Wichita, Knoxville and Garden City. To minimise travel expenses associated with the study, it is recommended to enroll in a site that is closest by."
Is this research project open for participant enrollment?
"It appears the clinicaltrial.gov records show that this study is not currently accepting new candidates; it was initially posted on July 15th 2021 and edited lastly April 25th 2022. Nonetheless, there are 1,677 other trials actively enrolling individuals right now."
How many participants are involved in this research?
"Unfortunately, at this juncture in time, the listed clinical trial is not currently recruiting. The first posting was on July 15th 2021 and it had its most recent update on April 25th 2022. If you are searching for other studies to participate in, there are presently 1 572 trials that seek patients with small cell lung carcinoma and 105 trials actively looking for participants who would like to take ocriplimab."
Has the regulatory body sanctioned Ociperlimab?
"There is clinical evidence backing the safety of Ociperlimab, which has earned it a score of 2 on our scale. However, Phase 2 does not entail any data that test its efficacy."
Share this study with friends
Copy Link
Messenger